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Abstract
Background: PC plays an important role in early diagnosis of health disorders, particularly migraine, due to the 
financial impact of this disease for the society and its impact on patients' quality of life. The aim of the study was to 
validate the self-administered MS-Q questionnaire for detection of hidden migraine in the field of primary care (PC), 
and to explore its use in this setting.
Methods: Cross-sectional, observational, and multicentre study in subjects above 18 years of age patients attending 
PC centers (regardless of the reason for consultation). A MS-Q score ≥ 4 was considered possible migraine. Level of 
agreement with IHS criteria clinical diagnosis (kappa coefficient), and instrument's validity properties: sensitivity, 
specificity, positive (PPV) and negative (NPV) predictive values were determined. The ability of the instrument to 
identify possible new cases of migraine was calculated, as well as the ratio of hidden disease compared to the ratio 
obtained by IHS criteria.
Results: A total of 9,670 patients were included [48.9 ± 17.2 years (mean ± SD); 61.9% women], from 410 PC centers 
representative of the whole national territory. The clinical prevalence of migraine according to the IHS criteria was 
24.7%, and 20.4% according to MS-Q: Kappa index of agreement 0.82 (p < 0.05). MS-Q sensitivity was 0.82 (95% CI, 0.81 
- 0.84), specificity 0.97 (95% CI, 0.98 - 0.99), PPV 0.95 (95% CI, 0.94 - 0.96), and NPV 0.94 (95% CI, 0.93 - 0.95). No 
statistically significant differences were found in the percentages of patients with de novo and hidden migraine 
identified by MS-Q and by IHS criteria: 5.7% vs. 6.1% and 26.6% vs. 24.1%, respectively.
Conclusions: The results of the present study confirm the usefulness of the MS-Q questionnaire for the early detection 
and assessment of migraine in PC settings, and its ability to detect hidden migraine.
Introduction
Migraine is a highly disabling disease with a prevalence of
about 10-12% in the general population. The risk of expe-
riencing migraine increases from the age of 16 years,
being 2 to 3-fold more frequent in women compared to
men [1]. In Spain, 14.1% of patients attending outpatient
neurology clinics are diagnosed of migraine and, when
referred to subjects less than 65 years of age, this percent-
age attains 20.7% [2].
On the other hand, primary care (PC) physicians play
an essential role in the diagnosis and management of
migraine; over 90% of migraine patients attending outpa-
tient neurology clinics are referred from their family doc-
tors [3]. Furthermore, recent data have shown a
significant increase of the number of PC visits due to
migraine, from 9.4 visits per 1.000 patients in 1990, to 18
visits per 1.000 patients in 1998 [4], this involving an
important assistance load. However, migraine continues
being an underdiagnosed condition. Calculations indicate
that barely 50% of these patients visit their doctor trying
to find help [5] and, in many cases, a proper diagnosis and
treatment may take years [6-8]. In order to properly
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establish a diagnosis of migraine, it is essential to know
the IHS classification criteria and apply these criteria in
clinical practice [9]. However, a recent survey conducted
in 721 Spanish PC doctors, indicated that only half of
them knew this classification, and only 5.4% were using
this classification in daily clinical practice. Although this
lack of knowledge, doctors stated they were interested in
migraine and, compared to the mean time per visit for
other diseases, were devoting a longer time to migraine
patients [10].
Bearing in mind the impact of migraine on patients'
quality of life [11,12], and its socio-economic conse-
quences [13,14], an early approach to the disease is
becoming increasingly necessary. With this purpose and,
in accordance to recommendations of experts on man-
agement of migraine [7,15,16], instruments for early
detection have been developed in recent years, as the
Diagnostic Headache Diary [17], the UCSD Migraine
Questionnaire [18], the ID Migraine [19], the Brief Head-
ache Screen [20], the 3-Question Headache Screen [21],
and other [22-26], with the aim of assisting PC physicians
to identify migraine patients in the shortest possible time,
due to the important assistance load of health centers.
This would not only improve the clinical approach to the
diagnosis of migraine, but also contribute to improve
patients' awareness of their disease, as often patients are
not aware of this disorder and of its social, occupational,
and clinical implications [27,28].
Of the previously mentioned instruments, only ID
Migraine and 3-Question Headache Screen have demon-
strated their clinical usefulness, although the specificity
of the first one [19] and the sensitivity of the second one
[21] to identify migraine are low, this limiting their prac-
tical usefulness. In addition, these instruments have not
been validated yet for the Spanish population. In 2005, a
new instrument developed by a group of experts, based
on the International Headache Society (IHS) criteria, and
fulfilling the principles of medicine based on evidence,
was validated [29]. This is a self-administered question-
naire for the screening of migraine, known as MS-Q,
Migraine Screen Questionnaire that may be used both, in
clinical practice and research projects (see Figure 1). MS-
Q is rapidly executed by patients, and contributes to eas-
ily identify symptoms suspicious of migraine for a later
medical confirmation of the diagnosis. This renders MS-
Q a new instrument able to optimize the management of
migraine patients with an important saving of time.
Thus, it was reasonable to conduct the present study,
one of which primary objectives was the validation of
MS-Q questionnaire as an instrument for migraine
detection in daily PC medical practice, not previously val-
idated, as well as to determine the prevalence of migraine
and the ratio of hidden migraine.
Materials and methods
Study Design
A cross-sectional, observational, and multicentre study
was designed. Patients of both genders over 18 years of
age who attended PC centers for any reason were
recruited, and informed consent was obtained. Partici-
pant centers were randomly selected by regional quotes
to preserve the national representative nature according
to regional population weights. However, patients were
consecutively recruited. Patients unable to complete
questionnaires or to understand the study consent were
excluded. Due to the observational nature of the study
design, the investigator decision on the most appropriate
treatment for a particular patient was never interfered.
The conduct of the study should not involve additional
risks, complementary tests, or additional visits relative to
the management of migraine patients in daily clinical
practice. The study was approved by the IRB of the Uni-
versity Hospital of Valencia and was conducted in accor-
dance to the Helsinki declaration for research in the
human being.
Sample Size
As previously mentioned, it was estimated that in the
general population, the prevalence of migraine is differ-
ently distributed depending on gender. For this reason, to
estimate the specific prevalence of migraine by gender, it
was considered appropriate to take into account this
aspect. A previous study indicated 18.2% prevalence of
migraine among women, and 6.5% among men [30]. Tak-
ing women's prevalence for sample size calculation, as
this is the highest value and requires a higher sample size
(in order to obtain an adequate sample to accurately esti-
mate prevalence in both genders), a sample of 5,709 sub-
jects was estimated to provide an accuracy of ± 1% for the
calculation of prevalence of migraine in women with a
95% confidence interval.
The present study was foreseen to be conducted in the
PC setting and, as in accordance with 1999 data from the
Figure 1 Migraine Screen — Questionnaire (MS-Q).
INSTRUCTIONS: The questions below refer to the headaches or migraine episodes 
without headache that you may have experienced in your lifetime. Answer each 
question as indicated. If you are not sure how to answer a given question, please 
answer what you believe is most correct.
1. Do you have frequent or intense headaches?   0. No 1. Yes
2. Do your headaches usually last more than 4 hours?   0. No 1. Yes
3. Do you usually suffer from nausea when you have a headache?   0. No 1. Yes
4. Does light or noise bother you when you have a headache?   0. No 1. Yes
5. Does headache limit any of your physical or intellectual activities?   0. No 1. YesLáinez et al. BMC Neurology 2010, 10:39
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National Statistics Institute (INE) [31], 54.21% of subjects
who attend primary care and specialized centers, and
medical clinics were female patients, the 5,709 women
needed to estimate prevalence of migraine would repre-
sent 54.21% of the total sample to be recruited. Thus, a
total sample of 10,532 patients was estimated. With an
anticipated loss for the analysis of 5% of patients, a total
sample of 11,087 patients was to be recruited. The PASS
package, 2002 version was used for calculations.
Assessment Measures for the Diagnosis of Migraine
Patients fulfilling inclusion and exclusion criteria com-
pleted the self-administered questionnaire MS-Q for the
screening of migraine [29]. This questionnaire consists
on 5 questions related to frequency and characteristics of
h e a d a c h e ,  a s  w e l l  a s  t o  t h e  p r e s e n c e  o r  a b s e n c e  o f
migraine related symptoms. A score of 0 was obtained for
each negative answer (NO), and of 1 for each positive
answer (YES). A cutting-point indicating suspicion of
migraine was established at ≥ 4 points, while an <4 score
indicated no suspicion of migraine [29].
Regardless MS-Q results, doctors checked their suspi-
cion of a diagnosis of migraine according to their clinical
judgment and IHS diagnostic criteria [9]. The (diagnosis
of migraine according to clinical judgment- IHS) was
recorded on the case report form (CRF) with the follow-
ing question: (In accordance to your clinical judgment
and to the recent IHS criteria for the diagnosis of migraine
(International Diagnosis of Migraine Criteria), does the
patient currently present a diagnosis of migraine?) with
the following possible answers: (yes or no). All partici-
pant doctors received training on IHS migraine criteria,
and a contact phone number was set up to clarify possible
questions about the study.
Data Analysis
In order to guarantee the project's quality, clinical data
were validated executing computer filters based on vali-
dation rules, to identify missing values or inconsistencies
of clinical data relative to the case report form (CRF) and
the protocol. After review, inconsistent data were modi-
fied in the database according to the CRF, provided possi-
ble inconsistencies had emerged from errors generated
during data tabulation process. At any time, the reliability
and rigor of the analysis was guaranteed. The SPSS®, ver-
sion 12.0.1 statistical program was used for all statistical
analysis.
Data were descriptively analyzed, mean, standard devi-
ation, and 95% confidence intervals calculated for quanti-
tative variables, and frequencies for qualitative variables,
in the overall and by gender samples. Patients socio-
demographic and clinical variables: age, gender, family
past history of migraine (yes/no), previous diagnosis of
migraine (yes/no), type of migraine, type of health center
where patient's migraine was being treated, and the rea-
son for the current visit were collected. Thereafter, and
according to the study primary objective, prevalence of
suspected diagnosis of migraine according to MS-Q, with
the corresponding two-way 95% confidence interval, was
determined both, for the overall and by gender samples.
Subsequently, based on the results obtained for the MS-Q
questionnaire and according to clinical judgment/IHS,
concordance in the presence or absence of diagnosis of
migraine suspicion was analyzed by kappa index calcula-
tion. The following ranges are recommended for inter-
pretation of the Kappa index (Landis) [32]: 0.40-0.59
(moderate concordance); 0.60-0.79 (substantial concor-
dance), and ≥ 0.8 (excellent concordance). Additionally,
the following indicators of validity and safety of the ques-
tionnaire as a test to detect migraine were estimated: sen-
sitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), positive probability ratio
(PPR), and negative probability ratio (NPR).
In some cases, data on fulfillment of IHS migraine diag-
nosis criteria were not reported or were missing. How-
ever, when in other CRF sections migraine was specified
as a concomitant disease, the patient received treatment
with the indication of (migraine), the reason for visit was
(migraine), or the patient had a previous diagnosis of
migraine, a diagnosis of migraine according to clinical
judgment/IHS was considered for that patient. In case of
data inconsistency relative to clinical diagnosis of
migraine (inconsistency between diagnosis data and
other CRF data), the analysis of diagnosis of migraine
concordance between MS-Q questionnaire and clinical
judgment/IHS was repeated after excluding these data
from the analysis (analysis with refined IHS criteria).
The percentage of patients with a de novo PC diagnosis
by MS-Q was calculated, i.e., the percentage of patients
with no previous diagnosis of migraine who indicated a
total scores ≥ 4 points in the questionnaire during the
visit, and the percentage of patients with de novo diagno-
sis in accordance to clinical judgment/IHS. Last, the per-
centage of (hidden migraine) was calculated, i.e.,
percentage of patients with de novo diagnosis vs. total
number of migraine patients diagnosed by both methods
(clinical judgment/IHS, and MS-Q questionnaire).
In case of normal distribution, comparisons were made
by a Student T test for independent samples (Gauss
adjustment by a Kolmogorov-Smirnov test), by a Mann-
Whitney U test for non-normal quantitative variables,
and by a Chi-square test for nominal variables. A two-
way p value < 0.05 was considered significant.
Results
Description of the Overall Valuable Sample
A total of 410 investigators from 371 PC health centers
representative of the whole national territory recruited aLáinez et al. BMC Neurology 2010, 10:39
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total sample of 9,670 patients of which 324 patients
(3.4%) not fulfilling any of the inclusion criteria were
excluded: 1% were under 18 years of age, 0.54% were
unable to complete questionnaires or understand the
s t u d y  i n f o r m e d  c o n s e n t,  a n d  f o r  1 . 8 %  o f  p a t i e n t s  d a t a
were not sufficient to estimate the study primary variable
(MS-Q questionnaire). In the total valuable sample (n =
9.346), 61.9% were female patients with a mean age of
48.9 years (SD: 17.2), and the largest part were over 40
years (65%). Male patients mean age was higher: 50.1 (SD:
17.2) vs. 48.2 (17.2) years, p < 0.001.
A 26.3% of patients indicated a family past history of
migraine, and 21.1% had a previous diagnosis of
migraine. Among these patients, the most common type
of migraine was without aura (41.4%), and most patients
attended PC centers for disease management (74.1%,
Table 1). Reasons for consultation were the following:
administrative reason, prescription or work leave (18.2%),
review (10.6%), and disease (56.3%). Neurological dis-
eases represented the third reason for consultation
(8.6%), being migraine the most frequent: 85.9% (Table 2).
Prevalence of Migraine
Diagnosis of migraine suspicion according to MS-Q 
questionnaire
MS-Q questionnaire mean total score was 1.6 (1.8) for
the overall sample: 1.0 (1.5) for men, and 1.9 (1.9) for
women, p < 0.001. Significant differences in the percent-
age of affirmative answers of all questionnaire items were
observed depending on gender, with higher frequencies
found among women (p < 0.05). MS-Q questionnaire
total score was ≥ 4, the cutting-point for migraine suspi-
cion, in 20.4% (95% CI: 19.5% - 21.2%) of patients. Statis-
tically significant differences were observed depending
on gender, and scores > 4 were more frequent among
female patients: 26.2% (25.1% - 27.3%) for women vs.
11.0% (10.0%-12.0%) for men; p < 0,001.
Diagnosis of migraine according to clinical judgment -IHS
The percentage of patients with a diagnosis of migraine
according to clinical judgment-IHS at the time of visit
was 24.7% (23.7% - 25.6%). A  h i g h e r  p r e v a l e n c e  o f
migraine was observed among women compared to men:
31.0% (29.7% - 32.2%) vs. 14.3% (13.1% - 15.5%) respec-
tively; p < 0,001.
Validity of MS-Q for the suspicion of migraine diagnosis
Results of MS-Q questionnaire validity as a screening test
for migraine, using the clinical judgment-IHS as the refer-
ence diagnosis are shown on Table 3. Cohen Kappa coef-
ficient of agreement, and sensitivity, specificity, PPV,
NPV, PPR, and NPR indicators are shown for the original
analysis and the refined analysis (after exclusion of
patients with inconsistent data). In the original analysis
the Kappa coefficient was 0.82, and 0.84 in the refined
analysis, this indicating an excellent concordance
between the two analyzed variables. Sensitivity, specific-
ity, PPV, NPV, PPR, and NPR indicators obtained in the
refined analysis were equal or higher than those obtained
Table 1: Background of migraine in overall and by gender samples
Male (%) Female (%) Overall (%) p1
Family past history of migraine
Yes 19.6 30.5 26.3 <0.001
Previous diagnosis of migraine?
Yes 12.4 26.3 21.0 <0.001
Type of migraine(2)
With aura 32.5 32.8 32.7 0.010
Without aura 35.3 43.1 41.4
With and without aura 27.5 20.2 21.8
Other 4.8 4.0 4.1
Where is your migraine being controlled?
Primary care 77.9 73.1 74.1
Neurology 10.2 12.3 11.8
Other 3.9 3.6 3.7 0.527
Primary care and Neurology 7.8 10.4 9.8
Primary care and other 0.0 0.2 0.2
Neurology and other 0.0 0.2 0.1
Primary care, Neurology and other 0.3 0.3 0.3
1Chi-square testLáinez et al. BMC Neurology 2010, 10:39
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Table 2: Reasons for the present visit: diseases or other related reasons.
Reason for visit Number of patients2 Percentage3
Diseases 5,259 56.3
Muscle -- skeletal diseases 1,182 12.6
Respiratory diseases 899 9.6
Neurological diseases1 803 8.6
Cardiovascular diseases 654 7.0
Gastrointestinal -- Hepatic diseases 361 3.9
Uro-gynecological diseases 290 3.1
Various signs and Symptoms 270 2.9
Psychiatric diseases 268 2.9
Endocrine -- Metabolic diseases 264 2.8
Dermatologic diseases 251 2.7
Organs of senses diseases 236 2.5
Infectious diseases 27 0.3
Malignancies 17 0.2
Other disease-related reasons 2,654 28.4
Administrative -- Prescriptions -- Work leaves 1,703 18.2
Review --Routine control 994 10.6
1690 of these patients with migraine (85.93%); 2A patient could simultaneously have > one reason; 3Percentages calculated from overall evaluated 
patients.
Table 3: MS-Q questionnaire validity properties being the diagnosis of reference that obtained according to clinical judgment -IHS in 
overall and by gender samples.
In the overall 
sample, 
according to 
IHS criteria
Validity of MS-Q questionnaire
Kappa Sensitivity Specificity PPV NPV PPR NPR
Overall
Original 
database
(N = 8.073)
0.82* 0.82 (0.81 - 0.84) 0.97 (0.97 - 0.97) 0.90 (0.89 - 0.91) 0.94 (0.94 - 0.95) 27.66 (23.93 - 31.97) 0.18 (0.17 - 0.20)
Depurated 
database
(N = 7.528)
0.84* 0.82 (0.81 -- 0.84) 0.98 (0.98 - 0.99) 0.95 (0.94 -- 0.96) 0.94 (0.93 - 0.95) 49.00 (40.02 -- 60.01) 0.18 (0.16 - 0.20)
Gender
Male
(N = 3.076)
0.79* 0.77 (0.73 - 0.81) 0.98 (0.98 - 0.99) 0.88 (0.85 - 0.91) 0.96
(0.94 --0.95)
44.08 (32.85 -- 59.16) 0.24 (0.20 -- 0.28)
Female
(N = 4.997)
0.82* 0.84 (0.82 -0.86) 0.96 (0.95 - 0.97) 0.91
(0.89 - 0.92)
0.94 (0.93 - 0.95) 21.32 (18.06 - 25.17) 0.17 (0.15 - 0.19)
PPV: Positive Predictive Value; NPV: Negative Predictive Value; PPR: Positive Probability Ratio; NPR: Negative Probability Ratio. * p < 0.001Láinez et al. BMC Neurology 2010, 10:39
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in the original analysis. Minimum MS-Q validity index,
i.e., for the original analysis, were the following: sensitiv-
ity = 0.82, specificity = 0.97, PPV = 0.90, NPV = 0.94%,
PPR = 27.66 y NRP = 0.18.
The analysis by gender of these indicators indicated
slightly higher MS-Q Kappa index and sensitivity values
in the female group, while specificity, PPR, and NPR val-
ues where higher in the male group (table 3).
Diagnosis of De Novo and Hidden Migraine
The mean percentages of patients with suspicious de novo
diagnosis were 5.7% by MS-Q, and 6.1% by clinical judg-
ment-ICH, and no statistically significant differences
were found between both diagnostic methods (Table 4).
With both methods, the women group indicated a signifi-
cant higher percentage of de novo diagnosis compared to
the men group.
No statistically significant differences were found
between percentages of hidden migraine identified by
b o t h  m e t h o d s .  M e a n  p e r c e n t a g e s  o f  h i d d e n  m i g r a i n e
were 24.0% (clinical judgment-IHS), and 26.6% (MS-Q
questionnaire). For this variable, the mean percentage of
hidden migraine was higher among men compared to
women. However, these differences were not statistically
significant: 29.4% (24.8% - 33.9%) vs. 26.0% (23.8% -
28.3%) with MS-Q questionnaire, and 25.5% (21.4% -
29.6%) vs. 23.9% (21.8% - 26.1%) with IHS criteria (Table
4).
Discussion
As anticipated, the observed prevalence of migraine,
24.7% by clinical judgment-IHS, and 20.4% by MS-Q
questionnaire, was higher than the prevalence reported in
studies conducted in general population samples [33-37],
as non-selected patients attending PC centers were
included. 5.7% of the patients attending a visit had a MS-
Q diagnosis of de novo migraine. This represents 26.6% of
hidden migraine when a de novo diagnosis is referred to
the migrainous population recruited for the study, and
confirms the usefulness of this questionnaire in common
medical practice. These data are very similar to those
obtained by the clinical diagnosis in accordance to IHS
criteria in the same population: 6.1% and 24,1%, respec-
tively. Regarding differences by gender, prevalence of
migraine in women was higher compared to men, consis-
tently with other epidemiologic studies [5,37-40], as well
as percentages of female patients with de novo, and hid-
den migraine diagnoses.
In this study, the percentage of hidden migraine
revealed the magnitude of the problem of underdiagnosis
among migrainous patients and, as previously mentioned,
a proper diagnosis and treatment may take several years
[3,6-8]. A study conducted in neurology clinics indicated
that 23.9% of migraine patients referred form PC were
not receiving any type of treatment, while among patients
attending neurology clinics without a previous PC diag-
n o s t i c  a p p r o a c h  w a s  8 5 . 7 %  [ 3 ] .  T h i s  d a t a  i n d i c a t e  t h e
importance of the diagnosis when a patient has to initiate
treatment, bearing in mind the level of disability both, in
work and day life activities, this disorder produces
[14,35].
On the other hand, as already observed in other previ-
ous studies of our sanitary area [41], migraine was found
to be the primary neurological disease evaluated in PC
centers, representing up to 85.93% of consultations for
neurological disorders, and most patients were managed
in PC centers (74.1% of patients vs. 11.8% managed in
neurology specialist centers). It is important to underline
the role of the PC physician for the detection and classifi-
cation of patients with headache, in order to directly treat
them at the PC level, or to refer these patients to a spe-
Table 4: Percentage of patients with de novo and hidden migraine in overall and by gender samples.
Percentage of patients1 Population MS-Q questionnaire Clinical judgment - IHS Difference
Diagnosis de novo2 Overall sample 5.7% (5.2% - 6.2%) 6.1% (5.5% - 6.6%) 3.1%
(-1.1% - +3.7%)
Male 3.4% (2.8% - 4.0%) 3.7% (3.0% - 4.4%) 3.3%
(-1.2% - +5.9%)
Female 7.2% (6.5% - 7.9%) 7.5% (6.8% - 8.2%) 3.2%
(-1.3% - +6.9%)
Hidden migraine Overall sample 26.6% (24.7% - 28.6%) 24.1% (21.4% - 29.6%) 1.4%
(-1.4% - +4.2%)
Male 29.4% (24.8% - 33.9%) 25.5% (21.4% - 29.6%) 2.9%
(-2.3% - +10.0%)
Female 26.0% (23.8% - 28.3%) 23.9% (21.8% - 26.1%) 2.1%
(-1.0% - +5.2%)
1 Percentages from the number of valid cases were calculated (data not reported in some cases). 2 Statistically significant differences were 
observed depending on the gender group (p < 0.001; Chi-square test).Láinez et al. BMC Neurology 2010, 10:39
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cialized level when a headache of uncertain origin or of a
more serious nature than migraine is suspected [7,42]
In addition, the study tested a new use of the instru-
ment, its implementation at primary care level. MS-Q
indicated to be an easy and simple to implement instru-
ment for early detection of migraine in PC, and its imple-
mentation should result in a more appropriate diagnostic
and therapeutic management of patients and, thus, a
lower load for the society and patients. These statements
are based on the concordance with the IHS criteria clini-
cal diagnosis, determined by the Kappa index, shown in
the validation of the MS-Q questionnaire in PC, that can
be considered good, with a range of 0.82 to 0.84 depend-
ing on the sample used, original or refined sample. Nev-
ertheless, both values are higher than the Landis criteria
recommended value of 0.7 [32]. In this sense, the similar-
ity between the results observed in a non-selected popu-
lation attending PC centers are those observed during
instrument's development, which included working and
neurological clinics populations, is to be underlined.
However, in the PC setting, the instrument indicated to
be more specific, 97% specificity, but less sensitive, 82%
sensitivity, although within the appropriate limits for a
screening test [29,43]. Other psychometric properties of
the analysis were almost optimal, with PPV and NPV ≥
90%.
On the other hand, the comparison between MS-Q and
other recent and similar questionnaires for the screening
of migraine (ID Migraine [19] y Brief Headache Screen
[20]) psychometric properties, confirmed that MS-Q
questionnaire psychometric properties are more appro-
priate for a screening instrument. The instrument indi-
cated a specificity higher than the other (0.75 and 0.93,
respectively), and its sensitivity was higher than that of ID
Migraine (0.75), and Brief Headache Screen (0.78) when
used in chronic migraine patients. MS-Q also indicated a
greater sensitivity than that observed for the 3-Question
Headache Screen questionnaire [21], which properly clas-
sified 77% of the 3.014 migraine patients included in the
instrument's validation study.
The present study, however, presents some limitations.
First, the test-retest reliability assessment of the question-
naire is still pending; due to the important difficulties
found in common medical practice. In a non-selected
population, MS-Q seemed to slightly underestimate the
actual prevalence of migraine using clinical judgment --
IHS in this setting, although showed good indicators in
accordance with the mentioned criteria. In addition, in
contrast with Brief Headache Screen, MS-Q could not
discriminate between patients with chronic and episodic
migraine. On the other hand, this instrument was vali-
dated in Spanish from Spain, and might need subsequent
validations before being used in other Spanish contexts.
Last, due to the magnitude of patients recruitment in our
study, we did not assess the incidence of incorrect diag-
noses as, due to the possibility of erroneous migraine
diagnosis, an expert panel would had been necessary to
review patients' diagnoses [8].
Any research focusing the early detection of this dis-
ease will be welcome; the amount of years migraine
patients spend without a proper diagnosis and treatment
is unacceptable. In addition, it is essential that patients
become conscious of their disease, as this is the first step
to request medical care, receive treatment, as well as to
follow day life recommendations to improve their quality
of life and have positive consequences on their social and
professional areas. Finally, because migraine may gener-
ally be identified early in life and is associated with multi-
ple co-morbidities, that effective screening tool can
define migraine and a population with other potential
health risks to the primary care provider. Then, using
migraine screening as a sentinel sign of other possible
health conditions.
Conclusions
In conclusion, although the previously mentioned limita-
tions, it can be stated that, based on the results of the
present study, the MS-Q questionnaire is a useful instru-
ment for early detection and assessment of migraine also
in the PC setting as, in addition of its good psychometric
properties, only consists on five questions, resulting in
the most feasible of the questionnaires used in this set-
ting, and may save a very valuable time in PC centers.
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